Understanding Provider Treatment Approaches for the Provision of Gender-Affirming Hormones in the Current US Political Climate.

Providers reviewed patients' medical history, social supports, and comorbidities when prescribing gender-affirming hormone therapy in accordance with informed consent models.

• Interviews were conducted with US providers in 2024.
• Providers reported reviewing medical history, social supports, and comorbidities as part of their standard prescribing approach.
• This approach was described as consistent with informed consent models of care.

Providers prescribed GAHT formulations that aligned with patients' individual goals.

• Providers tailored GAHT formulations to match the specific goals of each patient.
• This individualized approach was reported as part of the informed consent model framework.
• The study was conducted through qualitative interviews in 2024.

GAHT prescribers monitored patients' health regularly and maintained open communication with patients.

• Regular health monitoring was reported as a standard component of GAHT prescribing practice.
• Open communication with patients was identified as a key element of provider treatment approaches.
• These practices were described as part of the informed consent model.

GAHT prescribers followed clinical standards to mitigate risks and maximize benefits, applying similar standards of care as those used for cisgender patients.

• Providers reported following clinical standards comparable to those applied to cisgender patients.
• The approach was characterized as aimed at mitigating risks and maximizing benefits.
• This finding emerged from qualitative interviews with US providers conducted in 2024.
• The study was conducted in the context of increasing political attacks on transgender people's access to GAHT in the United States.